Royal Bank of Canada Has $293.69 Million Position in GSK PLC Sponsored ADR $GSK

Key Points

• Royal Bank of Canada has increased its stake in GSK PLC Sponsored ADR by 5.7%, now owning 7,581,079 shares valued at approximately $293.7 million.
• The company recently reported earnings of $1.23 EPS for the last quarter, exceeding analysts' expectations of $1.12, while its revenue was up 1.3% year-over-year.
• GSK announced a quarterly dividend of $0.4206 per share, leading to an annual payout of $1.68 with a yield of 4.2%.

Royal Bank of Canada boosted its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,581,079 shares of the pharmaceutical company's stock after buying an additional 411,869 shares during the period. Royal Bank of Canada owned 0.37% of GSK worth $293,692,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. HHM Wealth Advisors LLC grew its stake in shares of GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after purchasing an additional 460 shares during the period. Costello Asset Management INC purchased a new position in GSK during the 1st quarter valued at approximately $31,000. Richardson Financial Services Inc. raised its stake in GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after purchasing an additional 472 shares in the last quarter. Olde Wealth Management LLC purchased a new position in GSK in the first quarter worth about $36,000. Finally, Cary Street Partners Investment Advisory LLC increased its position in shares of GSK by 525.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock valued at $39,000 after purchasing an additional 852 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of NYSE GSK traded up $0.40 during trading hours on Wednesday, reaching $39.36. The stock had a trading volume of 4,206,712 shares, compared to its average volume of 3,012,819. The firm has a 50-day moving average of $38.46 and a 200-day moving average of $38.28. The firm has a market cap of $80.17 billion, a price-to-earnings ratio of 18.22, a PEG ratio of 1.72 and a beta of 0.53. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $44.26. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The firm had revenue of $10.64 billion for the quarter, compared to analysts' expectations of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.GSK's quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.3%. GSK's dividend payout ratio (DPR) is currently 77.78%.

Analyst Ratings Changes

GSK has been the topic of a number of research reports. Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a research report on Sunday, August 3rd. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Six analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus target price of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.